Literature DB >> 31719662

Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations.

Aurelie Houlier1,2, Daniel Pissaloux1,2, Ingrid Masse2, Franck Tirode2, Marie Karanian1,2, Laura B Pincus3, Timothy H McCalmont3, Philip E LeBoit3, Boris C Bastian3, Iwei Yeh3, Arnaud de la Fouchardière4,5.   

Abstract

We report a series of 33 skin tumors harboring a gene fusion of the MAP3K8 gene, which encodes a serine/threonine kinase. The MAP3K8 fusions were identified by RNA sequencing in 28 cases and by break-apart FISH in five cases. Cases in which fusion genes were fully characterized demonstrated a fusion of the 5' part of MAP3K8 comprising exons 1-8 in frame to one of several partner genes at the 3' end. The fusion genes invariably encoded the intact kinase domain of MAP3K8, but not the inhibitory domain at the C-terminus. In 13 (46%) of the sequenced cases, the 3' fusion partner was SVIL. Other recurrent 3' partners were DIP2C and UBL3, with additional fusion partners that occurred only in a single tumor. Clinically, the lesions appeared mainly in young adults (2-59 years of age; median = 18), most commonly involving the lower limbs (55%). Five cases were diagnosed as Spitz nevus, 13 as atypical Spitz tumor, and 15 as malignant Spitz tumor. Atypical and malignant cases more commonly occurred in younger patients. Atypical Spitz tumors and malignant Spitz tumors cases tended to show epidermal ulceration (32%), a dermal component with giant multinucleated cells (32%), and clusters of pigmented cells in the dermis (32%). Moreover, in atypical and malignant cases, a frequent inactivation of CDKN2A (21/26; 77%) was identified either by p16 immunohistochemistry, FISH, or comparative genomic hybridization. Gene expression analysis revealed that MAP3K8 expression levels were significantly elevated compared to a control group of 57 Spitz lesions harboring other known kinase fusions. Clinical follow-up revealed regional nodal involvement in two of six cases, in which sentinel lymph node biopsy was performed but no distant metastatic disease after a median follow-up time of 6 months.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31719662     DOI: 10.1038/s41379-019-0384-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

1.  Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis.

Authors:  K M Erny; J Peli; J F Lambert; V Muller; H Diggelmann
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

2.  Melanomas of childhood.

Authors:  S SPITZ
Journal:  Am J Pathol       Date:  1948-05       Impact factor: 4.307

3.  The Genetic Evolution of Melanoma.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  N Engl J Med       Date:  2016-03-10       Impact factor: 91.245

  3 in total
  9 in total

1.  Novel insights into the BAP1-inactivated melanocytic tumor.

Authors:  Michele Donati; Petr Martinek; Petr Steiner; Petr Grossmann; Tomas Vanecek; Liubov Kastnerova; Isabel Kolm; Martina Baneckova; Pietro Donati; Irina Kletskaya; Antonina Kalmykova; Josef Feit; Petr Blasch; Diana Szilagyi; Alfonso Baldi; Paolo Persichetti; Anna Crescenzi; Michal Michal; Dmitry V Kazakov
Journal:  Mod Pathol       Date:  2021-12-02       Impact factor: 7.842

2.  Morphologic features in a series of 352 Spitz melanocytic proliferations help predict their oncogenic drivers.

Authors:  Thibault Kervarrec; Daniel Pissaloux; Franck Tirode; Mahtab Samimi; Julien Jacquemus; Christine Castillo; Arnaud de la Fouchardière
Journal:  Virchows Arch       Date:  2021-11-11       Impact factor: 4.064

3.  Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.

Authors:  Anne Zaremba; Philipp Jansen; Rajmohan Murali; Anand Mayakonda; Anna Riedel; Manuel Philip; Christian Rose; Jörg Schaller; Hansgeorg Müller; Heinz Kutzner; Inga Möller; Nadine Stadtler; Julia Kretz; Antje Sucker; Agnes Bankfalvi; Elisabeth Livingstone; Lisa Zimmer; Susanne Horn; Annette Paschen; Christoph Plass; Dirk Schadendorf; Eva Hadaschik; Pavlo Lutsik; Klaus Griewank
Journal:  Int J Cancer       Date:  2022-07-11       Impact factor: 7.316

Review 4.  The Morpho-Molecular Landscape of Spitz Neoplasms.

Authors:  Carlo Alberto Dal Pozzo; Rocco Cappellesso
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

Review 5.  The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification.

Authors:  Tiffany W Cheng; Madeline C Ahern; Alessio Giubellino
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

6.  Prognostic value of LECT2 and relevance to immune infiltration in hepatocellular carcinoma.

Authors:  Jiangfeng Qin; Weijie Sun; Hui Zhang; Zihao Wu; Jiapei Shen; Wenhai Wang; Yuanyuan Wei; Yanyan Liu; Yufeng Gao; Honghai Xu
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

Review 7.  The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice.

Authors:  Gerardo Ferrara; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

Review 8.  Melanoma pathology: new approaches and classification.

Authors:  I Yeh; B C Bastian
Journal:  Br J Dermatol       Date:  2021-05-31       Impact factor: 11.113

9.  Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.

Authors:  Chiel F Ebbelaar; Anne M L Jansen; Lourens T Bloem; Willeke A M Blokx
Journal:  Virchows Arch       Date:  2021-04-13       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.